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Background: The persistence of antibiotic resistance depends on the fitness effects of resistance elements in the
absence of antibiotics. Recent work shows that the fitness effect of a given resistance mutation is influenced by
other resistance mutations on the same genome. However, resistant bacteria acquire additional beneficial
mutations during evolution in the absence of antibiotics that do not alter resistance directly but may modify the
fitness effects of new resistance mutations.
Results: We experimentally evolved rifampicin-resistant and sensitive Escherichia coli in a drug-free environment,
before measuring the effects of new resistance elements on fitness in antibiotic-free conditions. Streptomycin-
resistance mutations had small fitness effects in rifampicin-resistant genotypes that had adapted to antibiotic-free
growth medium, compared to the same genotypes without adaptation. We observed a similar effect when
resistance was encoded by a different mechanism and carried on a plasmid. Antibiotic-sensitive bacteria that
adapted to the same conditions showed the same pattern for some resistance elements but not others.
Conclusions: Epistatic variation of costs of resistance can result from evolution in the absence of antibiotics, as well
as the presence of other resistance mutations.
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The persistence of antibiotic-resistant bacteria depends on
how resistance, in the form of chromosomal mutations or
horizontally acquired elements such as plasmids, affects
fitness relative to antibiotic-sensitive genotypes in the
absence of antibiotics [1,2]. Recent work shows that the
fitness effects of resistance mutations often vary depending
on the presence of other resistance mutations on the same
genome [3-7]. However, resistance evolution will often be
accompanied by the fixation of additional mutations that
do not confer resistance but increase fitness in the present
environment, either because resistant bacteria evolve in
heterogeneous hosts or natural environments where the
optimal genotype changes over time, or because the cost of
resistance causes selection for compensatory mutations
(e.g. [8-13]). Any impact of adaptation in the absence
of antibiotics on the subsequent cost of additional resistance* Correspondence: alex.hall@env.ethz.ch
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reproduction in any medium, provided the ormutations therefore potentially modulates costs of
resistance in natural populations of pathogens.
Epistatic interactions have been observed among
different resistance elements [3-6,14,15], and among
different beneficial mutations during adaptation to
novel environments [16-19]. However, interactions between
the two types of mutations in terms of how they influence
fitness in the absence of antibiotics are less clear. In this
paper we ask whether adaptation of antibiotic-resistant and
sensitive bacteria to the same antibiotic-free environment
alters the fitness effects of additional resistance ele-
ments that confer resistance against other antibiotics.
To test for this possibility, we experimentally evolved
rifampicin-resistant (RifR) and rifampicin-sensitive
(RifS) E. coli in liquid growth medium in the laboratory,
before inserting mutations that conferred resistance to
streptomycin (StrR), shown schematically in Figure 1.
StrR mutations on rpsL change the structure of ribosomal
protein S12 and interfere with target binding in the
presence of streptomycin [20-22]. To determine whether
observed effects were specific to rpsL mutations, we car-
ried out parallel experiments with a plasmid that confersral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and





(1) Evolution in the 







K43N K88R RSF1010 









Figure 1 Construction of different genotypes and associated resistance phenotypes. (1) The wild type and three RifR genotypes evolved
for approximately 200 generations in liquid LB. (2) Additional resistance elements were inserted in the form of StrR mutations on rpsL (K43N or
K88R) or a SulR + StrR plasmid (RSF1010).
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The plasmid we used (RSF1010) has a broad host range
and encodes resistance to streptomycin by enzymatic
modification [23]. Therefore our experiment incorporated
multiple distinct antibiotic-resistance mechanisms. We
measured the fitness effects of resistance elements by pair-
wise competition assays, allowing us to quantify the effects
of additional resistance elements for RifR and RifS bacteria
both before and after adaptation. In several cases we
found that the cost of a new resistance element was
smaller in genotypes that had adapted to our experimental
environment compared with the same genotypes without
adaptation, although RifR and RifS bacteria showed
different patterns for some resistance elements.
Methods
Bacterial strains and growth conditions
In all experiments we used E. coli MG1655 grown at
37°C. To isolate mutants resistant to either rifampicin
or streptomycin (RifR or StrR), we plated independent
cultures of the wild type onto LB agar supplemented with
50 mg/L rifampicin [24] or 25 mg/L streptomycin. After
24 h incubation at 37°C we picked individual colonies,
restreaked to purify genotypes and confirm resistance,before growth for ~2 h in liquid LB and storage at −80°
C in 25%v:v glycerol. Rifampicin-resistance mutations
were identified by sequencing the central resistance-
determining region of rpoB as described previously
[24]; streptomycin-resistance mutations were identified by
sequencing part of rpsL using primers fwd 5'-ATGATG
GCGGGATCGTTG-3' and rev 5'-CTTCCAGTTCAGATT
TACC-3' [5]. All three of the RifR mutations (D516G,
S512F, I572S) and both StrR mutations (K43N and K88R)
have been previously associated with resistance to
these antibiotics in E. coli [5,12,25]. The SulR + StrR
plasmid RSF1010 was obtained from the Deutsche
Sammlung von Mikroorganismen und Zellkulturen
(DSMZ, Braunschweig, Germany). We constructed double-
resistant genotypes, with two resistance mutations or one
resistance mutation plus the plasmid, by transduction
or transformation as described below.
Experimental evolution in the absence of antibiotics
We initiated selection lines with each of the three RifR
genotypes (D516G, I572S, S512F) and three replicate
lines with the wild type (Figure 1). Each selection line
was grown in 100 μl liquid LB medium and diluted
1000-fold into fresh medium approximately every 12 h, as
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200 generations, we plated every population onto LB agar
and isolated a single colony from each, which we then grew
for 2 h in liquid LB and stored at −80°C. We checked for
reversion to rifampicin-sensitivity (RifS) in the evolved
clones derived from resistant genotypes by plating on LB
agar supplemented with rifampicin, but observed none.
This confirmed that the colony isolates used in the
present study remained RifR, although it does not
exclude the possibility of revertants at low frequency
in evolved populations. This procedure yielded nine
different genotypes in addition to the wild type (left-hand
side of Figure 1): three RifR genotypes that had not
adapted to LB, three RifR genotypes that had adapted to
LB (RifR-evolved), and three RifS genotypes that had
adapted to LB (RifS-evolved).
Addition of streptomycin resistance mutations and
plasmid
We used P1 transduction to insert either K43N or K88R
into each of the nine genotypes described above, plus
three independent replicates of the wild type. We followed
[26] with few modifications. Briefly, a lysate of each
donor strain was prepared by growth with phage P1
at low multiplicity of infection until lysis was visible,
then transduced to the relevant recipient genotype by
growth in LB for 20 min, followed by addition of sodium
citrate, further incubation for 1 h, plating on LB agar plus
streptomycin and sodium citrate, and restreaking three
times before isolating a single colony at random and
storing at −80°C. All constructed genotypes were verified
by resequencing rpsL. Transductions were done in a
single temporal block; for one genotype (I572S + K88R) a
different StrR mutation was acquired during the isolation
procedure; for D516G +K43N, no colonies were obtained
after repeated attempts; these are excluded from further
analysis.
Plasmid RSF1010 is a natural, nontransmissible, broad-
host range plasmid of the IncQ incompatibility group
conferring resistance to sulfonamide and streptomycin
[23]. We extracted the plasmid from cells grown in
LB using the PureYield Plasmid Miniprep Kit (Promega).
We then transformed the nine isolated genotypes and
three replicates of the wild type using TSS Transformation
[27]. Briefly, strains were grown in LB to OD600 0.3 and
chilled on ice for 10 min before adding an equal volume
of ice cold 2× TSS (TSS is LB with 10% w:v PEG8000, 5%
v:v DMSO, 50 mM MgSO4 at pH 6.5) and incubation on
ice for another 30 minutes. We then added 1 ml of
competent cells to 1 μl (~100 ng) of the plasmid prep
and incubated on ice for one hour. After incubation
at 37°C for one hour to allow expression of the resistance
genes, we plated cells on LB agar supplemented with
30 mg/L streptomycin. For each transformation a singlecolony was isolated at random, grown for 2 h in liquid LB
and stored at −80°C.
The fitness effects of transduced mutations and the
plasmid were reproducible in independently constructed
replicates of the wild type: fitness did not differ signifi-
cantly among different isolates for any of the resistance
elements in our experiment (K43N: F2,4 = 3.00, P = 0.16;
K88R: F1,4 = 0.05, P = 0.83; plasmid: F2,6 = 1.33, P = 0.33).
To check that the plasmid was not lost during competition
assays, we plated all competitions that included a
plasmid-carrying genotype on tetrazolium arabinose
(TA) plates, where streptomycin-resistant genotypes
form white colonies as described below, and on LB
agar supplemented with 30 mg/L streptomycin, on
which plasmid-carrying genotypes can grow but the
wild type cannot. We observed approximately the
same number of colonies on streptomycin plates as
white colonies on TA plates (paired t-test: t35 = 1.49,
P = 0.14), indicating that the plasmid was maintained
throughout the competition.
Fitness measurements
We measured the competitive fitness of each genotype
against a marked strain: E. coli K12 MG1655 Δara,
which is otherwise isogenic to the wild type and forms
red colonies on TA agar (tryptone 1%, yeast extract
0.1%, NaCl 0.5%, L(+)arabinose 1%, TTC 0.005%). For
each competition, we grew independent cultures of both
competitors overnight in liquid LB, before mixing them
1:1 v:v and diluting 1000-fold into fresh LB media. We
estimated the frequency of each competitor by plating
the culture on TA agar before and after two growth
cycles using the same protocol as during experimental
evolution. We then calculated relative fitness, w, as 1 + s,
where s is the selection coefficient s = ln(Rfinal / Rinitial) / t,
where Rfinal and Rinitial are the ratios of the competing
genotypes at the beginning and end of the assay and t is
assay duration in generations [5,28,29]; in batch culture t
can be approximated as log2(Nfinal/Ninitial), where N is total
population size. We discounted each score by the cost of
the Δara marker [5], which was not significantly different
from zero (−0.025 on average; P = 0.06). To calculate the
fitness effects of StrR mutations or the plasmid in a given
genetic background, we took the difference in fitness (Δw)
between the same strain with and without K43N, K88R or
the plasmid.
RifR, RifR-evolved and RifS-evolved genotypes lacking
either StrR mutations or the plasmid were each assayed in
three different blocks: once after the evolution experiment
to test for adaptation [24], once alongside genotypes with
K43N or K88R, and once alongside genotypes carrying the
plasmid. The correlation between fitness scores relative to
the wild type measured for these genotypes in different
blocks was high (r2 = 0.91, 0.94, 0.92), and there was no
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indicating that fitness values of different genotypes
relative to each other were repeatable across blocks of
assays. In each block, competitions were replicated
three times independently, and nine times for the wild
type. Additional file 1: Table S1.1.2 Testing for chaperone (DnaK and GroEL) overproduction
The best-described molecular mechanism for buffering
against the fitness effects of deleterious mutations is the
overproduction of molecular chaperones [30-32], enzymes
that assist in correct protein folding [33]. To determine
whether variation of costs of resistance among genotypes
in our experiment could be explained by variation in
chaperone production, we measured levels of the two
key chaperones DnaK and GroEL [34] using western
blots. Cells were harvested by centrifugation from
mid-exponential cultures, resuspended in 1× SDS-PAGE
sample buffer and boiled for 10 minutes. SDS-PAGE and
immunoblotting with mouse-monoclonal anti-DnaK and
anti-GroEL antibodies (Enzo Life Sciences) was carried out
according to standard procedures. ImmunStar Western C
Substrate Kit (BioRad) was used for detection in conjuction
with horseradish peroxidase-conjugated anti-Mouse lgG
secondary antibody (Amersham). Blots were imaged
using the ChemiDoc XRS + CCD Sytem (BioRad) and
analyzed using ImageJ 1.46 (Rasband, W.S., ImageJ,
U. S. National Institutes of Health, Bethesda, Maryland,































Figure 2 Adaptation of resistant and sensitive bacteria. Three
RifR genotypes, denoted on the x-axis by their amino acid changes,
and three replicates of the wild type (WT) were evolved for
approximately 200 generations in antibiotic-free LB medium as
described previously [24]. White and hatched bars show scores
before and after evolution respectively. Each bar shows average ± s.
e. competitive fitness relative to the wild type from nine
independent assays, conducted in three temporal blocks; for the
wild type before evolution standard error is shown for 27 assays.Statistical analyses
We tested for adaptation to LB by a paired t-test using
the average fitness of each genotype before and after
experimental evolution. We tested for variation of the
response to selection among genotypes by analysis of
variance including genotype and assay block as factors.
To test whether adaptation to LB altered the average fitness
effects of additional resistance elements (StrR mutations or
the plasmid) we conducted paired t-tests, taking the average
fitness effect (Δw) of each resistance element on each
genetic background before and after evolution, measured
in the same block of competition assays. We analyzed
variation of fitness effects among genotypes that had or
had not adapted to LB by analyses of variance with geno-
type as a factor. Additionally, we tested pairwise epistatic
interactions of RifR mutations with StrR mutations or the
plasmid in genotypes that had not adapted to LB. We did
this using the multiplicative model described by [5] and
results are shown in Additional file 2: Table S2. Finally, to
test for differences in levels of chaperones DnaK and
GroEL we used pairwise t-tests with non-pooled standard
deviation, correcting for multiple comparisons using the
Bonferroni method.Results
Adaptation in antibiotic-free conditions
Antibiotic-resistant (RifR) bacteria and the antibiotic-
sensitive wild type increased in fitness over approximately
200 generations of evolution in LB growth medium
(paired t-test: t5 = 6.20, P = 0.002; Figure 2). The change in
fitness after experimental evolution varied among different
evolved genotypes (F5,31 = 52.99, P < 0.0001). Among Rif
R
genotypes, the response to selection was relatively large
for genotypes derived from D516G and S512F, which
had lower fitness than the wild type at the start of
the experiment, compared with I572S that had a fitness
advantage. After experimental evolution, RifR and RifS
genotypes had similar levels of fitness on average
(Welch’s t-test: t2.35 = 0.40, P = 0.72; Figure 2). Thus,
despite initial variation, resistant and sensitive genotypes
adapted to experimental conditions and converged upon
similar levels of competitive fitness, as shown previously
for a wider range of rpoB mutants including the three in
this study [24].
Fitness effects of streptomycin resistance mutations
The fitness effects of StrR mutations were smaller on
average in genotypes that had adapted to LB compared
to the same genotypes without adaptation (paired t-test:
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grounds, K43N was more costly on average than K88R
(mean fitness effect ± s.d.-K43N:-0.11 ±0.07; K88R:-0.01
±0.04; Figure 3a,b).
For K43N, all of the RifR-evolved and RifS-evolved
genotypes we tested paid a smaller cost of resistance
than the same genotypes without evolution in LB
(Figure 3a). Among genotypes that had not adapted
to LB, the cost was similar in S512F and the wild
type, but comparatively small for I572S. This represents
antagonistic pairwise epistasis between I572S and K43N:
the cost of having both mutations was smaller than
expected from their independent effects on the wild type
(Additional file 2: Table S2). Among evolved genotypes,
the cost of K43N also varied depending on genetic
background (F4,10 = 12.84, P < 0.001), but in every case
it was less costly than without evolution in LB.
When streptomycin resistance was due to K88R, the
fitness cost was smaller after adaptation to LB for
both of the RifR genotypes we tested, although this
only represented statistically significant variation for
S512F (Figure 3b). The fitness effect of K88R varied
among genotypes that had not adapted to LB (F2,9 = 4.67,
P = 0.04), being costly on average in RifR genotypes but
not the wild type. K88R was also approximately neutral
for two out of three evolved wild type (RifS) genotypes,
and for the remaining one it had a small positive fitness
effect. Consequently, adaptation to LB had no effect on
average for the cost of K88R in RifS genotypes (F1,3 = 0.31,
P = 0.62). By contrast, K88R was costly to RifR genotypes
before, but not after experimental evolution in LB.
In summary, for one StrR mutation (K43N) the fitness
cost was consistently lower for evolved genotypes than
the same genotypes without adaptation to LB. A similar
effect was observed for the other StrR mutation on RifR
genetic backgrounds, but not for RifS genotypes, where
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Figure 3 Effect of adaptation on the cost of additional resistance elem
or (c) plasmid RSF1010 either before (white bars) or after (hatched bars) ad
effects of adaptation, as determined by pairwise t-tests assuming unequal
the wild type before evolution, bars show the average of three independeevolution in LB on average. Thus, the fitness effects of
StrR mutations varied epistatically depending on both
adaptation in the absence of antibiotics and on the
presence of other resistance mutations.Fitness effects of an antibiotic-resistance plasmid
Insertion of the plasmid RSF1010, conferring resistance
to sulfonamides and streptomycin, had a marginal cost
on average (mean fitness effect ± s.d. = −0.03 ± 0.05), but
this varied considerably among genotypes depending on
adaptation to LB and RifR mutation (Figure 3c). There
was no difference on average between the cost of
RSF1010 in genotypes that had evolved in LB and those
that had not (paired t-test: t5 = 1.29, P = 0.25), although
in some cases the fitness effect of the plasmid was
clearly lower in evolved genotypes. Specifically, RSF1010
was less costly for genotypes with RifR mutations D516G
or I572S after they had evolved in LB (Figure 3c), but
there was no difference for S512F or any of the RifS evolved
genotypes. This variation was driven by a comparatively
large fitness cost in two of the unevolved RifR genotypes,
reflecting negative pairwise epistasis between the plasmid
and D516G and I572S (Additional file 2: Table S2). Thus,
the plasmid was costly to D516G and I572S before
but not after evolution in antibiotic-free LB; other
genotypes paid a comparatively small cost of carrying
the plasmid.Buffering of fitness effects is not due to overexpression
of chaperones
The phenotypic effects of deleterious mutations can be
buffered by overproduction of molecular chaperones, of
which GroEL and DnaK are the two most important and
best studied [32,34]. However, we found no upregulation
of either chaperone in evolved genotypes (pairwise t-tests:


































ents. Each bar shows the fitness effect of (a) rpsL K43N, (b) rpsL K88R
aptation to LB growth medium. Asterisks denote statistically significant
variances. Each bar shows mean ± s.e. for three independent assays; for
ntly constructed genotypes, each assayed three times.
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We measured the fitness effects of three different
antibiotic-resistance elements (two StrR mutations and a
SulR + StrR plasmid) in RifR and RifS genotypes that had
or had not adapted to antibiotic-free growth medium. In
cases where additional resistance elements were costly
to genotypes that had not evolved in LB, the cost was
consistently smaller after adaptation to our experimental
environment. For one of the StrR mutations this pattern
was consistent across RifR and RifS genotypes, suggesting
that the relatively small cost of new resistance mutations
after adaptation in the absence of antibiotics is not
specific to resistant bacteria. For the other StrR mutation
and the plasmid, the cost was greatest in RifR genotypes
that had not adapted to LB, and evolved genotypes
showed a small cost or even a benefit of resistance by
comparison. These results show that evolution in the
absence of antibiotics can alter the fitness effects of
new resistance elements, but this pattern depends on
the identity of the new mutation and on the presence
of other resistance mutations.
Consistent with previous studies [3,5,6,15,35], we
found pairwise epistatic interactions among resistance
elements on the same genetic background: out of seven
multiple-resistant genotypes with a RifR mutation and
either an StrR mutation or the plasmid, three showed
significant deviations from a multiplicative model of
fitness (Additional file 2: Table S2). Moreover, our
finding that evolution in the absence of antibiotics alters
the fitness effects of additional resistance elements
suggests that epistatic variation of costs of resistance
can also be caused by beneficial mutations that fix in
the absence of antibiotics.
To our knowledge, the best characterized mechanism
that actively buffers against deleterious mutations is
over-expression of molecular chaperones [34,36,37]. This
did not explain our findings: the two main chaperones,
DnaK and GroEL, were not overproduced in evolved geno-
types. This is perhaps unsurprising, given that selection for
chaperone-mediated buffering is expected to depend on
intense genetic drift [38] or high mutation rates [39,40],
which is supported by experiments with viruses [41]. In the
absence of direct selection for a buffering mechanism, the
impact of adaptation on the cost of StrR mutations and the
plasmid is probably an indirect effect of mutations that
were under positive selection for their effects on growth in
LB. By analogy, rpoB mutations that fix under selection for
rifampicin resistance have wide-ranging effects on the
bacterial phenotype, owing to direct effects on the function
of RNA polymerase and pleiotropic effects on the expres-
sion of other genes [42-44]. This is associated with altered
growth phenotypes in unselected environments [44,45]
and epistatic interactions with other resistance mutations
[5,6]. Although we lack a physiological understanding ofadaptation to LB, it is known to alter growth phenotypes in
unselected environments to a similar degree as rpoB
mutations in this experimental system [24]. This is
consistent with beneficial mutations fixed in LB having
indirect phenotypic effects that are unrelated to improved
growth in LB but may generate epistatic interactions.
Our experiments included a limited set of resistance
elements (three different types, including chromosomal
mutations and a plasmid). Therefore we do not draw any
general conclusions about how adaptation will influence
the cost of new resistance elements. However, our results
do show that adaptation in the absence of antibiotics can
cause epistatic variation of fitness costs. In support, a
recent study demonstrated variation of the fitness effects of
rifampicin-resistance mutations among antibiotic-sensitive
E. coli genotypes [46]. This is consistent with epistatic
variation of fitness costs due to mutations at loci unrelated
to drug resistance. We also stress that with only one
selection line for each RifR genotype, variation in the
outcomes of evolution among evolved RifR genotypes
does not necessarily reflect an effect of starting genotype.
Stochastic processes during adaptation, including the
random appearance and loss of beneficial mutations
[47], will also contribute to variation among individual
selection lines. Therefore, while we found differences on
average between RifR and RifS evolved genotypes, and
between evolved and nonevolved genotypes, we did not test
whether the effect of adaptation varies among genotypes
with different rifampicin-resistance mutations.
Directions for further work include identifying the physio-
logical mechanisms by which adaptation to antibiotic-free
conditions can alter the costs of new resistance elements,
and how general such effects are. For example, expression
profiling of resistant and sensitive genotypes that have and
have not been experimentally evolved could be used to find
cellular functions that are altered by resistance mutations
and adaptation, both independently and in combination. To
determine whether adaptation has a general effect on the
cost of additional resistance mutations would require
experiments with other model organisms, antibiotics
and growth media. In particular, testing whether com-
pensatory mutations that ameliorate the deleterious
effects of one resistance mutation [8,10-13] can buffer
against the effects of resistance elements at other loci
would be relevant to the broader question of how selection
acts on antibiotic resistance across genetic backgrounds.
Conclusions
We observed epistatic variation of the fitness costs
associated with antibiotic resistance, stemming from
interactions between different resistance elements as
observed previously [3,5,6] and from interactions between
resistance elements and beneficial mutations that fixed dur-
ing adaptation to drug-free conditions. This is potentially
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of pathogenic bacteria. In chronic infections, such as
those caused by Pseudomonas aeruginosa in cystic fibrosis
patients, bacteria fix multiple mutations during a single
infection, many of which are unrelated to resistance evolu-
tion [48-50]. Other pathogens such as Mycobacterium
tuberculosis, which often carry antibiotic resistance ele-
ments, also fix mutations that are beneficial in the absence
of antibiotics [51]. If such mutations influence the cost of
subsequent resistance mutations, as they did in our
experiment, then a better understanding of epistasis
between resistance elements and other types of mutations
will be important for predicting the likelihood that
multi-drug resistant bacteria will persist following different
types of treatment.
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